# Safety and Efficacy of CLL1 CAR-T Followed by Allogeneic Hematopoietic Stem Cell Transplantation in the Treatment of Relapsed/Refractory Acute Myeloid Leukemia

> **NCT07342244** · NA · NOT_YET_RECRUITING · sponsor: **Donghua Zhang** · enrollment: 18 (estimated)

## Conditions studied

- AML
- AML (Acute Myeloid Leukemia)

## Interventions

- **DRUG:** CLL1 CAR-T Cell Sequential Allogeneic Hematopoietic Stem Cell Transplantation

## Key facts

- **NCT ID:** NCT07342244
- **Lead sponsor:** Donghua Zhang
- **Sponsor class:** OTHER
- **Phase:** NA
- **Study type:** INTERVENTIONAL
- **Status:** NOT_YET_RECRUITING
- **Start date:** 2026-01-30
- **Primary completion:** 2028-12-20
- **Final completion:** 2029-12-20
- **Target enrollment:** 18 (ESTIMATED)
- **Last updated:** 2026-01-15


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT07342244

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT07342244, "Safety and Efficacy of CLL1 CAR-T Followed by Allogeneic Hematopoietic Stem Cell Transplantation in the Treatment of Relapsed/Refractory Acute Myeloid Leukemia". Retrieved via AI Analytics 2026-07-09 from https://api.ai-analytics.org/clinical/NCT07342244. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*